业务发展

业务发展

Business development
全部分类

R&D Mode

We are committed to transitioning from a traditional sales agency to an innovative pharmaceutical enterprise by integrating global R&D resources through independent and collaborative projects via the "license-in + MAH-backed development" R&D mode, aiming to address diverse clinical and market needs with a diversified pipeline. Our R&D activities include import registration, MAH-backed development, and license-in & development of modified and innovative drugs.

I. Import Registration

We specialize in introducing globally differentiated, high-quality products to China. With our robust registration capability, we conduct feasibility and market potential assessments, identify products suitable for the Chinese market for our global partners, handle import registration procedures, and manage post-approval marketing as well as full lifecycle management.

II. Co-development

Targeting high-technical barrier areas, we initiate projects for differentiated high-end generic and modified drugs with remarkable clinical needs and value. Through collaboration with academic pioneers, CROs and CDMOs at home and abroad, we conduct MAH-backed development of differentiated competitive products.

III. Innovative R&D

Focusing on unmet clinical needs in mental healthcare, we seek new targets, mechanisms and projects, and integrate global R&D resources via the "independent project initiation + co-development" mode. This advances the R&D of innovative drugs for psychiatric disorders, facilitating our gradual transition into an innovative pharmaceutical enterprise.